TLDR
- UNH rose 8.16% over the past week, with a near double-digit single-day rally
- CMS finalized a 2.48% Medicare Advantage reimbursement rate increase for 2027
- Bernstein raised its price target to $411 and reiterated a Buy rating
- HSBC upgraded UNH to Hold; Baird’s Michael Ha remains the lone Sell voice
- UNH is still down ~7% year to date and over 50% below its 2024 peak
UnitedHealth Group (UNH) had its best week in seven months, climbing over 8% after the US government delivered a surprise Medicare Advantage payment boost.
UnitedHealth Group Incorporated, UNH
The Centers for Medicare & Medicaid Services finalized a 2.48% increase in 2027 Medicare Advantage reimbursement rates. That was a sharp improvement from an earlier proposal that had rates staying nearly flat.
The announcement sparked a near double-digit rally in a single trading session. Investors had been bracing for the worst, so the higher rate came as a genuine relief.
Medicare Advantage has been a core growth engine for UNH for over a decade. But rising medical costs and tighter government funding had started squeezing margins, making this ruling a much-needed development.
Bernstein moved quickly after the news. The firm raised its price target on UNH to $411 and kept its Buy rating in place.
Analyst commentary from Bernstein suggested the CMS decision flips what could have been a roughly 4% hit to 2027 earnings into expected earnings growth of around 1.4%. That’s a meaningful swing.
HSBC analyst Sidharth Sahoo upgraded UNH to Hold on the same day. It was a measured move — not a full endorsement, but a sign that the risk profile had shifted.
One Holdout
Not everyone is buying the optimism. Baird’s Michael Ha held his Underperform rating, making him the only analyst with a sell-equivalent view among the 31 covering the stock.
Ha’s argument is that the payment increase may only be a temporary offset. He flagged that structural pressures on value-based care models haven’t gone away.
That’s a fair point worth keeping in mind. The Medicare Advantage business is still navigating a tricky environment, even with the better rate.
The Bigger Picture
UNH recently projected a decline in 2026 revenue — which could mark its first annual contraction in over three decades. Enrollment is expected to shrink across commercial, Medicare, and Medicaid plans.
The stock is still down about 7% year to date and sits more than 50% below its 2024 peak. The rally this week puts a dent in those losses, but the gap remains wide.
Still, Wall Street’s overall read is constructive. Of 31 analysts covering UNH, 22 have Buy ratings. The average 12-month price target points to roughly 17% upside from current levels.
Optum, UNH’s health services arm covering pharmacy benefits and care delivery, continues to provide some earnings stability as the core insurance business faces headwinds.
Investors are now watching Q1 2026 earnings closely. Medical cost trends and any updated guidance on Medicare Advantage profitability will be the key items on the agenda.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
